1. THE EFFECTS OF OKT4A MONOCLONAL ANTIBODY ON CELLULAR IMMUNITY OF NONHUMAN PRIMATE RENAL ALLOGRAFT RECIPIENTS
- Author
-
Robert B. Colvin, Frederic I. Preffer, Deborah Stroka, S. L. Wee, Cosimi Ab, and Jolliffe Lk
- Subjects
Male ,Interleukin 2 ,Cellular immunity ,medicine.drug_class ,Allosensitization ,CD8 Antigens ,medicine.medical_treatment ,Monoclonal antibody ,Cell Movement ,Animals ,Transplantation, Homologous ,Cytotoxic T cell ,Medicine ,Lymphocytes ,Immunity, Cellular ,Transplantation ,business.industry ,Antibodies, Monoclonal ,Immunosuppression ,Immunotherapy ,Kidney Transplantation ,Macaca fascicularis ,CD4 Antigens ,Immunology ,Interleukin-2 ,Lymphocyte Culture Test, Mixed ,business ,Immunosuppressive Agents ,CD8 ,medicine.drug - Abstract
Significant differences in cellular responses were found among allograft recipients treated with various OKT4A mAb protocols. Recipients of multiple infusion low-dose and 2-bolus OKT4A immunosuppressive regimens regularly showed potent donor-specific cytotoxic CD8+ and CD4+ intragraft T cells and donor-reactive PBMC in MLC tests. In contrast, PBMC isolated from recipients of high-dose OKT4A therapy generally showed very weak or no response to donor-antigens during the later posttransplant periods. Furthermore, an absence of IL2-responsive intragraft cells was found to correlate with stable graft function in these recipients. We conclude that OKT4A mAb, in high doses, can block allosensitization and induce donor-specific nonresponsiveness in vivo. An OKT4A-based therapy, therefore, may have the potential of inducing long-lasting donor-specific immunosuppression, or even tolerance.
- Published
- 1992